Previously undiscovered cannibis compound could lead to improved epilepsy treatment

(Medical Xpress)—Scientists at the University of Reading have demonstrated for the first time that a previously unstudied chemical in cannabis could lead to more effective treatments for people with epilepsy.

The team at the University's Department of Pharmacy and School of Psychology have discovered that cannabidivarin (CBDV) - a largely ignored found in cannabis - has the potential to prevent more seizures, with few side effects such as uncontrollable shaking, caused by many existing anti-epileptic drugs.

In the study, carried out by the University of Reading in collaboration with GW Pharma and Otsuka Pharmaceuticals, cannabidivarin strongly suppressed seizures in six different commonly used in epilepsy .

Cannabidivarin was also found to work when combined with drugs currently used to control epilepsy and, unlike other cannabinoids (unique components in cannabis) such as THC, is not psychoactive and therefore does not cause users to feel 'high'.

This video is not supported by your browser at this time.
Dr Ben Whalley talking about the discovery.

The findings are reported in the journal.

Dr Ben Whalley is leading the study at the University of Reading alongside colleagues Dr Gary Stephens and Dr Claire Williams.

Dr Whalley said: "This is an enormously exciting milestone in our investigations into non-psychoactive elements of cannabis as treatments for epilepsy.

"There is a pressing need for better treatments for epilepsy. It's a with no cure and currently in around one third of cases, the currently available treatments do not work, cause serious side-effects and increase fatalities. Currently prescribed drugs to prevent fits can cause significant side-effects to individuals' motion and that can adversely affect the quality of life for people who have to take them every day.

"Our work has highlighted the potential for a solution based on cannabinoid science.  It has shown that cannabidivarin is the most effective and best tolerated anticonvulsant plant cannabinoid investigated to date."

Dr Stephen Wright, R&D director at GW Pharmaceuticals said: "These results further underscore the potential of naturally-derived cannabinoids as medicines to treat a broad range of diseases. GW has established a track record of discovering and commercialising such compounds with Sativex now on the market for treating spasticity associated with multiple sclerosis and in late stage development for the treatment of cancer pain. Our research into CBDV has consistently produced highly promising results demonstrating its potential as a novel anticonvulsant and GW hopes during 2013 to advance CBDV into human clinical trials."

Following the discovery, scientists at Reading are investigating the mechanisms by which cannabidivarin works to reduce seizures and are testing CBDV in chronic models of epilepsy that closely mimic the clinical condition. This work will be completed by the end of 2012.

affects approximately 1% of people worldwide, and is caused by excessive electrical activity in the brain, which leads to that are in some cases fatal.

More information: Reference: Hill AJ, Mercier MS, Hill TDM, Glyn SE, Jones NA, Yamasaki Y et al. (2012) Cannabidivarin is anticonvulsant in mouse and rat in vitro and in seizure models.  Br J Pharmacol doi.wiley.com/10.1111/j.1476-5381.2012.02207.x

Related Stories

New direction for epilepsy treatment

Mar 28, 2011

If common anticonvulsant drugs fail to manage epileptic seizures, then perhaps the anti-inflammatory route is the way to go. That's according to Mattia Maroso and colleagues from the Mario Negri Institute for Pharmacological ...

Recommended for you

US aims for traumatic brain injury clinical trial success

1 hour ago

An unprecedented, public-private partnership funded by the Department of Defense (DoD) is being launched to drive the development of better-run clinical trials and may lead to the first successful treatments for traumatic ...

New learning mechanism for individual nerve cells

6 hours ago

The traditional view is that learning is based on the strengthening or weakening of the contacts between the nerve cells in the brain. However, this has been challenged by new research findings from Lund University in Sweden. ...

USC memory scientist Richard Thompson dies at 84

22 hours ago

Richard F. Thompson, the University of Southern California neuroscientist whose experiments with rabbits led to breakthrough discoveries on how memories are physically stored in the brain, has died. He was 84.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Shootist
3 / 5 (2) Sep 13, 2012
Cannabis. Like bacon, is there nothing it cannot do?